IRICoR is delighted by the commitment made by the ministère de l’Économie et de l’Innovation (MEI) in creating “Médicament Québec”, a major strategic hub whose mission is to promote greater autonomy and increase Quebec’s drive in drug discovery, development and production.
This large-scale project led by Université de Montréal, and got off the ground thanks to $13M in funding from the MEI. Through […]

At a recent special evening to mark the 30th anniversary of BIOQuébec, the organization welcomed the appointment of three new members to its board of directors. IRICoR is therefore pleased to announce the appointment of its President and CEO, Ms. Nadine Beauger, to the Board of Directors of BIOQuébec.
BIOQuébec is the largest Quebec network in biotechnology and life sciences. The […]

SCIENTIFIC COLLABORATION YIELDS NEW HOPE FOR CHILDREN AFFECTED BY RARE BLOOD DISORDER
 
The Alberta-based Canadian Glycomics Network (GlycoNet), which develops new carbohydrate-based drugs, vaccines and diagnostics, joined forces with Quebec-based IRICoR, a group that specializes in drug discovery and commercialization. Both are part of Canada’s Networks of Centres of Excellence program, which fosters academic, government and industry partnerships […]

IRICoR announces its participation in the 2nd edition of the BIO Digital conference to be held on June 10-11 and June 14-18, 2021. This industry event aims to create business opportunities among life science players from all over the world. It is also an opportunity for companies and institutions to develop partnerships of interest with complementary organizations, in particular through […]

Dr Rénaldo Bastista will be decorated, on June 22, with the title of Officer of the National Order of Quebec, on the occasion of the 35th ceremony of this illustrious organization.
Dr. Rénaldo Batista, CEO of the Oncopole, is one of the 43 exceptional people who will be honored this year with one of the three degrees of the National Order […]

Martinsried/Munich and Montréal, 10 April 2021. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today presents the screening and identification of novel immunogenic tumor-specific antigens (TSAs) derived from non-coding regions of the human genome at the American Association for Cancer Research Virtual Annual Meeting (AACR) 2021. The […]

MONTREAL, April 6, 2021 /CNW Telbec/ – Ovarian cancer is the 5th most common cancer among women, as well as one of the most fatal. It is estimated that 3,100 Canadian women will be diagnosed each year, and 55 per cent of them will not live beyond five years from their diagnosis.* To address these alarming statistics, IRICoR and Ovarian Cancer Canada joined forces […]

IRICoR, Université de Montréal, IRIC and Valence Discovery collaborate to design novel drug candidates for the treatment of levodopa-induced dyskinesia in Parkinson’s disease patients
 
A leading researcher at Université de Montréal will leverage IRICoR’s expertise in accelerating drug discovery projects and Valence’s AI-enabled platform to design highly selective drug candidates against a newly identified target.
 
MONTREAL and CAMBRIDGE, Mass., March 10, 2021 […]

IRICoR will attend the AUTM Annual Meeting, March 15-18, 2021.
AUTM’s Annual Meeting invites technology transfer professionals from around the globe to network, make deals and gain valuable insights from world-class speakers and panels.
If you would like to meet with IRICoR at AUTM 2021, please contact Jean-louis Brochu, M.Sc., Senior Intellectual Property Manager, who will represent IRICoR at this event:

By email : […]

Montreal, March 08, 2021 – On the occasion of International Women’s Day, Nadine Beauger, President and CEO of IRICoR was invited to participate in a most relevant panel discussion bringing together renowned female leaders from the ecosystem life sciences. BIOQuébec joined forces with Women In Bio and MassBio to present this panel.
The event, […]